Stoke Therapeutics Reports Third-Quarter Loss of $73.6 Million
Story updates
08:04:28 PM UTC
SquawkNews
Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patien
08:05:30 PM UTC
SquawkNews
STOKE THERAPEUTICS Q3 OPERATING INCOME USD -77.315 MILLION
08:15:05 PM UTC
SquawkNews
Stoke Therapeutics reported third-quarter 2026 revenue of $11.3 million and a net loss of $73.6 million, or $1.08 per share. Cash, cash equivalents and marketable securities totaled $358.8 million at quarter-end, which the company expects to fund operations into early 2028. The Phase 3 EMPEROR stud…